Novel Mutation Pair L858M/L861Q Caused Resistance to Both First- and Third-Generation EGFR Inhibitors, but Was Found to Be Sensitive to the Combination of Lapatinib and Erbitux.

Bejjanki, Harini; Bishnoi, Rohit; Reisman, David

Bejjanki, Harini; Bishnoi, Rohit; Reisman, David.

Affiliation

Bejjanki H; Department of Medicine, University of Florida, Gainesville, Florida.
Bishnoi R; Division of Hospital Medicine, Department of Medicine, University of Florida, Gainesville, Florida.
Reisman D; University of Florida, Gainesville, Florida. Electronic address: David.Reisman@medicine.ufl.edu.

J Thorac Oncol ; 12(10): e169-e170, 2017 10.

Article in En | MEDLINE | ID: mdl-28939152

Subject(s)

Cetuximab; ErbB Receptors/genetics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm/drug effects; Humans; Lapatinib; Lung Neoplasms; Mutation/drug effects; Protein Kinase Inhibitors; Quinazolines

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: ErbB Receptors / Cetuximab Type of study: Diagnostic_studies Limits: Humans Language: En Journal: J Thorac Oncol Year: 2017 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google